EMA Recommends VAXNEUVANCE Pneumococcal Vaccine for Approval EMA Recommends VAXNEUVANCE Pneumococcal Vaccine for Approval
The vaccine, which received FDA approval in July, protects against 15 strains of Streptococcus pneumoniae.International Approvals (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 15, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Alert Source Type: news

Vaccination Rates For Whooping Cough, HPV, Meningitis (And More) Plummeted During Covid Lockdown
Routine vaccinations fell across all age groups, according to a new study (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 7, 2021 Category: Pharmaceuticals Authors: Graison Dangor, Forbes Staff Tags: Healthcare /healthcare Innovation /innovation Breaking breaking-news Coronavirus Source Type: news

Pneumococcal vaccination reduces antibacterial failure and costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

The Gates Foundation ’s 2021 Report Shows That Childhood Vaccinations Dropped During the Pandemic—But There’s a Bright Side
This time last year, the Bill and Melinda Gates Foundation warned of a grim potential side effect from the COVID-19 pandemic: its disruptions to routine medical care could erase 25 years of progress on childhood vaccination, setting back global health by decades. The 2021 installment of the foundation’s annual Goalkeepers report, which details progress on 18 metrics related to global health, equity and sustainability, contains some good news and some bad news. Childhood vaccination rates have suffered during the pandemic—but only about half as much as the Gates Foundation originally predicted, signaling that ma...
Source: TIME: Health - September 14, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 embargoed study healthscienceclimate Source Type: news

Africa: Messenger RNA - How It Works in Nature and in Making Vaccines
[The Conversation Africa] Vaccines have long been an integral part of public health programmes around the world, reducing the spread and severity of infectious diseases. The success of immunisation strategies to protect children from diseases like polio, hepatitis B, and measles, and adults from influenza and pneumococcal disease, can be seen globally. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news

15-Valent Pneumococcal Vaccine Shows Promise in Infants 15-Valent Pneumococcal Vaccine Shows Promise in Infants
In a recent study, the 15-valent pneumococcal conjugate vaccine Vaxneuvance was noninferior to the currently available 13-valent pneumococcal vaccine in healthy infants.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 3, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Risk for Asthma at Age 4 Years Higher After Pneumonia in Infancy
Risk slightly higher after introduction of nationwide pneumococcal conjugate vaccine (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 1, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Pediatrics, Pulmonology, Allergy, Journal, Source Type: news

Universal Pneumococcal Vaccines May Increase Antibiotic Resistance Universal Pneumococcal Vaccines May Increase Antibiotic Resistance
Universal vaccines won't necessarily reduce antibiotic resistance in Streptococcus pneumoniae, but they may necessitate changes in vaccine policy.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - August 26, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2021 Category: Drugs & Pharmacology Source Type: news

Influenza and pneumococcal vaccination in elderly cost saving in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 29, 2021 Category: Drugs & Pharmacology Source Type: news

Community-acquired bacterial meningitis
Progress has been made in the prevention and treatment of community-acquired bacterial meningitis during the past three decades but the burden of the disease remains high globally. Conjugate vaccines against the three most common causative pathogens (Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae) have reduced the incidence of disease, but with the replacement by non-vaccine pneumococcal serotypes and the emergence of bacterial strains with reduced susceptibility to antimicrobial treatment, meningitis continues to pose a major health challenge worldwide. In patients presenting with bacterial m...
Source: Current Awareness Service for Health (CASH) - July 28, 2021 Category: Consumer Health News Source Type: news

Vaccine sales help GSK beat forecasts
Demand for jabs for meningitis, diphtheria and hepatitis recovers after pandemic disruption (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 28, 2021 Category: Pharmaceuticals Source Type: news

CDC: Advisory Committee on Immunization Practices (ACIP)
The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) is hosting a virtual meeting on September 29-30, 2021. The agenda will include discussions on cholera vaccine, hepatitis vaccines, herpes zoster vaccines, orthopoxvirus vaccine, pneumococcal vaccine, and tickborne encephalitis vaccine. Includes information on how to submit public comments or request permission to make a public comment during the meeting. Registration is not required and the meeting is open to the public, available online via a live webcast. (Source: Federal Register updates via the Rural Assistance Center)
Source: Federal Register updates via the Rural Assistance Center - July 26, 2021 Category: Rural Health Source Type: news

MenQuadfi (Meningococcal (Groups A, C, Y, W) Vaccine for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 21, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults
KENILWORTH, N.J.--(BUSINESS WIRE)-- (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) (pronounced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 16, 2021 Category: Drugs & Pharmacology Source Type: news

Commensal bacteria 'vaccine' may safely prep immune cells for meningitis-causing cousin
(American Association for the Advancement of Science) Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2021 Category: International Medicine & Public Health Source Type: news

Meningococcal B vaccine free for at-risk people in New Zealand
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

Twenty-Year Impact of Pneumococcal Conjugate Vaccines Twenty-Year Impact of Pneumococcal Conjugate Vaccines
A new report highlights the 20-year effect of pneumococcal conjugate vaccines in preventing pneumococcal disease in children.Emerging Infectious Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2021 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves 20-Valent Pneumococcal Vaccine (Prevnar) FDA Approves 20-Valent Pneumococcal Vaccine (Prevnar)
The vaccine is capable of protecting against 20 serotypes involved in most cases of invasive pneumonia and pneumococcal disease in the US. This may be a significant advance in reducing pneumonia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2021 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

FDA Approves Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for Adults Ages 18 Years or Older
First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia,1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 8, 2021 Category: Drugs & Pharmacology Source Type: news

Pfizer begins testing COVID-19 booster shot with pneumococcal vaccine
The pharmaceutical company Pfizer is studying a third dose of the vaccine and a pneumococcal vaccine candidate. (Source: Reuters: Health)
Source: Reuters: Health - May 25, 2021 Category: Consumer Health News Source Type: news

16 Candles? Time for Your Meningitis Shot, Molly Ringwald Says
MONDAY, May 24, 2021 -- Leslie Maier lost her son, Chris, to meningococcal meningitis more than 15 years ago, but by telling his story she hopes to educate other parents about this rare but potentially deadly illness that a vaccine can... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 24, 2021 Category: General Medicine Source Type: news

Teens Ages 12 to 15 Should Get Pfizer-BioNTech ’s COVID-19 Vaccine, Says a CDC Expert Panel
Following the US Food and Drug Administration’s decision on May 10 to extend emergency use authorization for the Pfizer-BioNTech vaccine to include 12- to 15-year olds, the Centers for Disease Control added its recommendation that teens in that age group should be vaccinated with the shot. The expert panel of the CDC’s Advisory Committee on Immunization Practices makes immunization recommendations, and determined that based on the evidence from a study of more than 2200 teens conducted by Pfizer-BioNTech, that the vaccine was safe and effective. During the day-long meeting, however, the members discussed whethe...
Source: TIME: Health - May 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Pneumococcal Vaccines Safe for Pregnant Women With HIV Pneumococcal Vaccines Safe for Pregnant Women With HIV
Pneumococcal vaccines PCV-10 and PPV-23 are equally safe and immunogenic in pregnant women with HIV, although PPV-23 administration might be more beneficial because it includes a wider range of serotypes, researchers say.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 12, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

The Most Important Thing Rich Countries Can Do to Help India Fight COVID-19
The Biden Administration is debating whether COVID-19 vaccine patents should be temporarily waived, given the devastating humanitarian crisis unfolding in India from the virus. There are two key factors that should drive the Biden team to agree to do so: first, there is strong precedent on waiving patents in the context of public health emergencies; second, the real-world effectiveness of most COVID-19 vaccines against symptomatic disease and transmission can temper the disaster. The Biden Administration will be making its decision on lifting some patent restrictions as early as May 5. India faces a catastrophe, with ove...
Source: TIME: Health - May 5, 2021 Category: Consumer Health News Authors: Dr. Monica Gandhi Tags: Uncategorized COVID-19 India Source Type: news

With Covid Vaccines for Teens and Kids, Timing Matters
There can be a seven- or eight-week window around Covid vaccines when other shots can ’t be given, so those who need them for camp, school or sports have to plan ahead. (Source: NYT Health)
Source: NYT Health - May 4, 2021 Category: Consumer Health News Authors: Perri Klass, M.D. Tags: Vaccination and Immunization Pediatric Inflammatory Multisystem Syndrome (PIMS) Coronavirus Risks and Safety Concerns Meningitis Youth Teenagers and Adolescence Children and Childhood Source Type: news

SII to start supplying 1st made-in-India pneumococcal conjugate vaccine to Centre from Wednesday
The SII has to supply 2.4 crore doses of the vaccine to the Health Ministry by December 2021. It will be sent to 37 consignees all over India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 6, 2021 Category: Pharmaceuticals Source Type: news

Dual influenza and pneumococcal vaccination cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. Will Have Enough COVID-19 Vaccines for All Adults by End of May, Biden Says
(WASHINGTON) — President Joe Biden said Tuesday that the U.S. expects to take delivery of enough coronavirus vaccines for all adult Americans by the end of May, two months earlier than anticipated, as his administration announced that drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved shot. With the bolstered supply, Biden also announced he would be using the powers of the federal government to direct all states to prioritize vaccinating teachers, and said the federal government would provide the doses directly through its pharmacy program. He challenged states to administe...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Authors: ZEKE MILLER, LINDA A. JOHNSON and JONATHAN LEMIRE/AP Tags: Uncategorized COVID-19 wire Source Type: news

Pneumococcal polysaccharide vaccine prevents ACS events in elderly, saves cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

ACIP Releases 2021 Child/Adolescent Vaccine Schedule ACIP Releases 2021 Child/Adolescent Vaccine Schedule
Changes include new recommendations on the influenza and meningococcal vaccines and guidance on COVID-19 vaccines.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2021 Category: Consumer Health News Tags: Pediatrics News Alert Source Type: news

Can AstraZeneca ’s Vaccine Prevent the Spread of COVID-19 Virus?
In a new—yet to be peer-reviewed—study, the pharmaceutical company AstraZeneca and its partners at the University of Oxford report that their COVID-19 shot may not only protect against disease but also help to prevent spread of the SARS-CoV-2 virus. The news was heralded by policy makers desperate to see a vaccine that can curb spread of the disease, but scientists have been a bit more cautious. If confirmed, the results would represent a breakthrough in the COVID-19 vaccine race. So far, the shots authorized or approved around the world have shown strong protection against moderate to severe disease, but haven...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

COVID-19 Vaccination information for health care professionals, BTS
This document provides information for respiratory health care professionals in relation to the current COVID-19 vaccination programme and covers issues that may arise in discussion with patients. This might include questions around safety or immune responses from patients with chronic respiratory disease, or on immunosuppression for lung conditions as well as more general questions around vaccines/immunisation programme, including Influenza, and pneumococcal vaccines. We also highlight the role of respiratory healthcare professionals as advocates for vaccination. A significant constituency of patients may be fearful or ...
Source: Current Awareness Service for Health (CASH) - February 4, 2021 Category: Consumer Health News Source Type: news

Pneumococcal vaccination in adults with diabetes: modest effect on costs of pneumococcal disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
Receipt of PCV13 alone or in combination with PPSV23 predicts fivefold reduced risk for SPD compared with no vaccination (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 29, 2021 Category: Respiratory Medicine Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
THURSDAY, Jan. 28, 2021 -- For veterans with inflammatory bowel disease (IBD), the risk for severe pneumococcal disease (SPD) is increased with Crohn disease and with more comorbidities, and pneumococcal vaccination is associated with a reduced risk... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 28, 2021 Category: Pharmaceuticals Source Type: news

Serum Institute launches India's first fully indigenously developed pneumococcal vaccine
PNEUMOSIL has been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates Foundation. This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries. (Source: The Economic Times)
Source: The Economic Times - December 29, 2020 Category: Consumer Health News Source Type: news

Vardhan launches India's first indigenously developed pneumococcal vaccine 'Pneumosil'
During clinical trials, Pneumosil was found to be safe and effective in the prevention of pneumonia and based on which Pneumosil has been licensed by the Drugs Controller General of India in July 2020 after approval from subject expert committee (SEC), he said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 28, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute develops first indigenous vaccine against pneumonia; to be launched next week
India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm. (Source: The Economic Times)
Source: The Economic Times - December 24, 2020 Category: Consumer Health News Source Type: news

Intellectual Property Monopolies Block Vaccine Access
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Dec 15 2020 (IPS) Just before the World Health Assembly (WHA), an 18 May open letter by world leaders and experts urged governments to ensure that all COVID-19 vaccines, treatments and tests are patent-free, fairly distributed and available to all, free of charge. Pious promises Leaders of Italy, France, Germany, Norway and the European Commission called for the vaccine to be “produced by the world, for the whole world” as a “global public good of the 21st century”, while China’s President Xi promised a vaccine developed by Chi...
Source: IPS Inter Press Service - Health - December 15, 2020 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Civil Society Development & Aid Economy & Trade Featured Global Headlines Health Human Rights Humanitarian Emergencies Poverty & SDGs TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

Cells to Society: Year of the Nurse / Global Impact
This article provides a theoretical clarification of the concept "social cohesion" as it relates to health behaviors and outcomes, uncovering the critical attributes, antecedents, and consequences of social cohesion and reflecting on its future in health literature.     Read more   View More Research ...
Source: Johns Hopkins University and Health Systems Archive - December 11, 2020 Category: Nursing Source Type: news

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four tr ials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vac cine or saline). ...
Source: Current Awareness Service for Health (CASH) - December 9, 2020 Category: Consumer Health News Source Type: news

Meningococcus B vaccine prevents disease with 79 per cent effectiveness in under 18s
Meningococcus group B, the most prevalent strain of meningococcal infection, is prevented with 79 per cent effectiveness in children and young adults inoculated with the 4CMenB vaccine, also known as Bexsero, according to a new collaborative study from researchers in Portugal and the UK and led by the University of Bristol which evaluated the vaccine ’ s performance in a real-world setting. The findings are published today [1 December] in the Journal of the American Medical Association (JAMA). (Source: University of Bristol news)
Source: University of Bristol news - December 1, 2020 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Population Health Sciences, Faculty of Life Sciences, Faculty of Life Sciences, School of Cellular and Molecular Medicine; Press Release Source Type: news

Meningococcus B vaccine prevents disease with 79 per cent effectiveness in under-18s
(University of Bristol) Meningococcus group B, the most prevalent strain of meningococcal infection, is prevented with 79 per cent effectiveness in children and young adults inoculated with the 4CMenB vaccine, also known as Bexsero, according to a new collaborative study from researchers in Portugal and the UK and led by the University of Bristol which evaluated the vaccine's performance in a real-world setting. The findings are published today [1 December] in the Journal of the American Medical Association (JAMA). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

An AstraZeneca Manufacturing Error Is Clouding Vaccine Study Results
LONDON — AstraZeneca and Oxford University on Wednesday acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine. A statement describing the error came days after the company and the university described the shots as “highly effective” and made no mention of why some study participants didn’t receive as much vaccine in the first of two shots as expected. In a surprise, the group of volunteers that got a lower dose seemed to be much better protected than the volunteers who got two full doses. In the low-dose group, AstraZeneca said,...
Source: TIME: Health - November 26, 2020 Category: Consumer Health News Authors: DANICA KIRKA / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news

Directed enhanced service specification for flu updated
An updated directed enhanced service specification (DES) for the seasonal flu and pneumococcal vaccination programme 2020/21 has been published. (Source: NHS Networks)
Source: NHS Networks - November 9, 2020 Category: UK Health Source Type: news

Two Thirds of US Teens Fail to Get Needed Vaccines Two Thirds of US Teens Fail to Get Needed Vaccines
Completion rates vary from 11.3% in Idaho to 56.4% in Rhode Island. Provider visits at age 16 or 17 and mandates for meningococcal ACWY are keys to uptake, researcher says.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 23, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news